Agomab Secures Cash Runway to 2029 with $208M IPO, Confirms Key Clinical Milestones for H2 2026
summarizeSummary
Agomab Therapeutics reported its full year 2025 financial results, highlighting a strong cash position of EUR116.5 million at year-end. Crucially, the company announced that the $208 million gross proceeds from its February 2026 IPO are expected to extend its cash runway into the first half of 2029. This significant capital infusion substantially de-risks the company's operations and provides a solid foundation for its clinical pipeline. Furthermore, Agomab confirmed positive interactions with the FDA for its Phase 2b study of ontunisertib in FSCD and remains on track to initiate both the Phase 2b FSCD study and a Phase 2 IPF study with AGMB-447 in the second half of 2026. Topline data from the OLE study for ontunisertib and the Phase 1b IPF study for AGMB-447 are also anticipated in H2 2026, providing multiple near-term catalysts for the stock.
At the time of this announcement, AGMB was trading at $10.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $514.2M. The 52-week trading range was $9.00 to $17.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.